Aim-To determine the relation of the low anticoagulant response phenotype with the Factor V Q506 (Leiden) mutation in a cohort of patients with thrombophilia. Methods-Fifty four patients with either a personal or family history of deep vein thrombosis were investigated both for their anticoagulant response by the activated protein C resistance test (APCR) and their genetic status in respect of the Leiden mutation by means of a PCR-RFLP method. Results-Low APCR ratios do not necessarily predict possession of the Leiden mutation. Conversely, normal ratios do not exclude the mutation. Of 14 individuals with low APCR ratios, the Leiden mutation was absent in five. Of the remainder, three were heterozygous and six homozygous. Of nine heterozygote individuals, only three had low APCR ratios. All patients homozygous for the defect had low APCR ratios. Conclusions-These results lend further weight to the hypothesis that the APC resistant phenotype results from more than one genetic defect and indicate the value of combined functional and molecular investigations in all patients with thrombophilia. (J Clin Pathol: Mol Pathol 1996;49:M223-M224) 
Activated protein C (APC) resistance is an inherited defect in anticoagulant response characterised by increased risk for thromboembolism. The main cause of the defect has been shown to be a point mutation in the Factor V gene (G to A), known as the Leiden mutation, resulting in an amino acid change from Arg to GIn.1 This substitution destroys the APC cleavage site on Factor Va, removing an important control on thrombin formation. The prevalence of this mutation in the normal population has been shown to be between 2 and 4%*2 3 The APC resistance test measures the prolongation of the clotting time in response to the addition of APC to patient plasma. A All analyses were performed using the Coatest APC resistance C kit. Briefly, one volume of plasma was mixed with APTT reagent and incubated at 37°C for five minutes. One volume of calcium chloride was added and clot formation timed. A second analysis was performed, replacing the calcium chloride with APC/calcium chloride (Human activated Protein C co-lyophilised with calcium chloride) and clot formation timed again. Clot formation was determined using an ACL 3000 instrument with time for detection extended to 150 seconds in accordance with the manufacturer's instruction.
The APC ratio, defined as clot time with APC plus calcium chloride/clot time with calcium chloride, was calculated for samples and controls. An APC sensitivity ratio S 2.2 was taken to indicate a defect in the anticoagulant response to APC, being the assay cut off value defined by screening 63 healthy volunteers (27 men, 36 women; age range 18-52 years). In the case of ratios below the established cut off point, results were confirmed by repeat analyses on fresh samples. With regard to the latter we find the PCR-RFLP approach used in the current study to be a method well suited for use in the routine diagnostic laboratory, being both relatively simple to perform and easy to interpret. Alternative approaches to analysis requiring probe hybridisation or direct DNA sequencing are limited in their application because of their technical complexity and requirement for more specialist facilities but could be used as adjuncts to PCR-RFLP or as stand-alone techniques if desired. We are currently involved in work to introduce sequence based analysis to our laboratory.
